WANBURY240.65

Wanbury Limited

· Pharma & Health
₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹789 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2025
Total Debt64.1110.0173.2173.2
Net Debt62.6106.6169.0169.0
Total Debt/Equity-1.953.942.922.92
Net Debt/Equity-1.913.812.852.85
Total Debt/EBITDA2.771.572.272.27
Net Debt/EBITDA2.701.522.211.92
Interest Coverage (EBIT/Interest)0.501.951.711.71
Total Debt/Total Capital %204.7779.7474.5174.51
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.